Medical management of miscarriage Pregnancy and Childbirth Other abnormal products of conception
Conditions
Interventions
In both groups, oral mifeprostone (200 mg) was given and then the misoprotol administered 48 hours later. The vaginal regimen was given once only. If no products were passed/seen, even on vaginal spec
Sponsors
South Tees Hospitals NHS Trust (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Women with an ultrasound diagnosis of (singleton) early foetal demise, with no medical contraindications or known allergy to misoprostol or mifepristone.
Exclusion criteria
Exclusion criteria: 1. Heavy smokers (of >20 cigarettes day) 2. Aged >35 years 3. Severe asthma 4. Cardiovascular disease, hypertension (blood pressure [BP] >160/100 mmHg) 5. Chronic adrenal, renal or hepatic failure 6. Porphyria or haemorrhagic disorders 7. Long term corticosteroid 8. Anticoagulant or non-steroidal anti-inflammatory drug (NSAID) therapy 9. Known allergy to mifepristone or misoprostol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinically diagnosed completion of miscarriage | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Parity, assessed at initial presentation 2. Anembryonic/embryonic early foetal demise assessed at time of ultrasound scan and miscarriage diagnosis 3. Side effects (pain, diarrhoea, vomiting), assessed during treatment and inpatient stay 4. Analgesia use | — |
Countries
United Kingdom
Outcome results
None listed